Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Aug;70(2):376–379. doi: 10.1038/bjc.1994.309

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.

C N Sternberg 1, W W ten Bokkel Huinink 1, J F Smyth 1, V Bruntsch 1, L Y Dirix 1, N A Pavlidis 1, H Franklin 1, S Wanders 1, N Le Bail 1, S B Kaye 1
PMCID: PMC2033513  PMID: 7914427

Abstract

Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic agent for the treatment of cancer. Forty patients with bidimensionally measurable advanced adenocarcinoma of the colon were treated with docetaxel 100 mg m-2 every 3 weeks as a 1 h infusion without routine premedication. Thirty-nine patients were eligible: 23 males and 16 females. Median age was 60 years (range 41-75) and WHO performance status 1 (0-2). Prior adjuvant chemotherapy was performed in four patients and prior radiotherapy in nine patients. Bidimensionally measurable disease sites included: liver in 26 patients, lymph nodes and abdominal/peritoneal masses in 13, lung/mediastinal masses in ten and subcutaneous nodes in four. The median number of cycles given was 2 (range 1-15). Thirty-three patients were evaluable for response. One patient (3%) achieved a complete response and two (6%) (95% confidence limits 0-14%) a partial response. Side-effects were similar to those observed in other studies. Docetaxel, given at this dosage and schedule, has minimal activity in the treatment of colorectal carcinoma.

Full text

PDF
376

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boring C. C., Squires T. S., Tong T. Cancer statistics, 1991. CA Cancer J Clin. 1991 Jan-Feb;41(1):19–36. doi: 10.3322/canjclin.41.1.19. [DOI] [PubMed] [Google Scholar]
  2. Bruckner H. W., Motwani B. T. Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol. 1991 Oct;18(5):443–461. [PubMed] [Google Scholar]
  3. Doroshow J. H., Multhauf P., Leong L., Margolin K., Litchfield T., Akman S., Carr B., Bertrand M., Goldberg D., Blayney D. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol. 1990 Mar;8(3):491–501. doi: 10.1200/JCO.1990.8.3.491. [DOI] [PubMed] [Google Scholar]
  4. Erlichman C., Fine S., Wong A., Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol. 1988 Mar;6(3):469–475. doi: 10.1200/JCO.1988.6.3.469. [DOI] [PubMed] [Google Scholar]
  5. HEIDELBERGER C., CHAUDHURI N. K., DANNEBERG P., MOOREN D., GRIESBACH L., DUSCHINSKY R., SCHNITZER R. J., PLEVEN E., SCHEINER J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957 Mar 30;179(4561):663–666. doi: 10.1038/179663a0. [DOI] [PubMed] [Google Scholar]
  6. Hansen R. M. Systemic therapy in metastatic colorectal cancer. Arch Intern Med. 1990 Nov;150(11):2265–2269. [PubMed] [Google Scholar]
  7. Horwitz S. B. Mechanism of action of taxol. Trends Pharmacol Sci. 1992 Apr;13(4):134–136. doi: 10.1016/0165-6147(92)90048-b. [DOI] [PubMed] [Google Scholar]
  8. Kemeny N. Role of chemotherapy in the treatment of colorectal carcinoma. Semin Surg Oncol. 1987;3(3):190–214. doi: 10.1002/ssu.2980030312. [DOI] [PubMed] [Google Scholar]
  9. McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. doi: 10.7326/0003-4819-111-4-273. [DOI] [PubMed] [Google Scholar]
  10. Poon M. A., O'Connell M. J., Moertel C. G., Wieand H. S., Cullinan S. A., Everson L. K., Krook J. E., Mailliard J. A., Laurie J. A., Tschetter L. K. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989 Oct;7(10):1407–1418. doi: 10.1200/JCO.1989.7.10.1407. [DOI] [PubMed] [Google Scholar]
  11. Ringel I., Horwitz S. B. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991 Feb 20;83(4):288–291. doi: 10.1093/jnci/83.4.288. [DOI] [PubMed] [Google Scholar]
  12. Schrijvers D., Wanders J., Dirix L., Prove A., Vonck I., van Oosterom A., Kaye S. Coping with toxicities of docetaxel (Taxotere). Ann Oncol. 1993 Aug;4(7):610–611. doi: 10.1093/oxfordjournals.annonc.a058599. [DOI] [PubMed] [Google Scholar]
  13. Valone F. H., Friedman M. A., Wittlinger P. S., Drakes T., Eisenberg P. D., Malec M., Hannigan J. F., Brown B. W., Jr Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol. 1989 Oct;7(10):1427–1436. doi: 10.1200/JCO.1989.7.10.1427. [DOI] [PubMed] [Google Scholar]
  14. Wani M. C., Taylor H. L., Wall M. E., Coggon P., McPhail A. T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971 May 5;93(9):2325–2327. doi: 10.1021/ja00738a045. [DOI] [PubMed] [Google Scholar]
  15. Weiss R. B., Donehower R. C., Wiernik P. H., Ohnuma T., Gralla R. J., Trump D. L., Baker J. R., Jr, Van Echo D. A., Von Hoff D. D., Leyland-Jones B. Hypersensitivity reactions from taxol. J Clin Oncol. 1990 Jul;8(7):1263–1268. doi: 10.1200/JCO.1990.8.7.1263. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES